This project focuses on cluster 5 DLBCL, for which a large collection of genetically engineered mice has been established. The project will expand on these efforts, to develop comprehensive and versatile in vivo preclinical platforms that employ a combination of large-scale in vitro vulnerability screening, and an in vivo validation tool box, to develop innovative and genomics-guided approaches for the treatment of genetically-defined high-risk DLBCL patients. We will also perform an in vivo CRISPR/Cas9 screen in CAR-T cells, to search for T cell-specific genes and pathways which propel the anti-lymphoma CAR-T cell response.
PRINCIPAL INVESTIGATOR
Department of Hematology and Stem Cell Transplantation
University Hospital Essen
Hufelandstraße 55
45147 Essen
Project Interactions
-
A03
LUBAC and its enzymatic activities in the development and therapy of ABC-diffuse large B-cell lymphoma
Prof. Dr. rer. nat. Henning Walczak, Dr. rer. nat. Gianmaria Liccardi -
B04
T cell-based mechanisms of immune evasion in aggressive B cell lymphomas
Prof. Dr. med. Dr. rer. nat. Sandrine Sander -
C01
Tumor heterogeneity and genomic instability in classical Hodgkin lymphoma
Prof. Dr. rer. nat. Ralf Küppers -
C05
Characterization of Richter-transformed lymphoma and genomic instability as a potential vulnerability in 17p-deleted lymphomas
Prof. Dr. med. Björn Chapuy, Prof. Dr. med. Barbara Eichhorst